A Phase 4 interventional study of Ursodeoxycholic Acid 250 Mg Oral Capsule and Omega -3 fatty acids in Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight and Acute Lymphoblastic Leukemia, sponsored by Ain Shams University. Active, not recruiting at 2 sites in Egypt. Open to participants aged 5 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-09.
Sponsored by Ain Shams University · Phase 4, Interventional, and Prevention
Non Alcoholic Fatty Liver Disease (NAFLD) is a spectrum of disease, ranging from simple fatty deposition (steatosis) to inflammation (steatohepatitis), fibrosis, cirrhosis, and end-stage liver failure. In childhood, it may be associated with a metabolic syndrome or with obesity, or even in normal children. Liver biopsy has always been the gold standard method for diagnosing and staging NAFLD. However, the urge of non-invasive biomarkers or imaging techniques has been recommended. This study will evaluate the use of the LIVERFASt biomarkers for early detection and staging of NAFLD.
Nonalcoholic fatty liver disease (NAFLD), defined as abnormal hepatic accumulation of macrovesicular fat in the absence of other etiologies. NAFLD is becoming increasingly prevalent in the pediatric population in direct correlation with the emergence of childhood obesity as a significant pediatric health problem.
Most patients with NAFLD are asymptomatic, and the disease is detected incidentally. Some patients complain of fatigue, malaise, and vague right upper abdominal discomfort. The most common signs are hepatomegaly and laboratory abnormalities, which include a 2 to 4 fold elevation of serum aminotransferase levels, while other liver function test results are usually normal unless advanced liver disease is present. Most are obese, many have diabetes mellitus, hypercholesterolemia, or hypertriglyceridemia.
This study will recruit 195 children aged between 5-18 years divided in 3 groups, each 65 participants: (P1) overweighted (BMI between 84th\& 94 th centiles) or obese (BMI>95th)and (P2) children on maintenance chemotherapy for acute lymphoblastic leukemia at risk for NAFLD, compared with control healthy children matched for gender and age (P3). Each participant will be subjected to history taking , clinical examination and anthropometric measures: weight,height,BMI,waist circumference and triceps skin fold thickness. Body composition will also be done.
Thereafter each participant will have a baseline LIVERFASt, U/S and Transient elastography assessments and will be randomly assigned by a computer based program to one of two interventional arms: Arm(1): which comprises Mediterranean Diet (MD) for 12 weeks, Supplementation of omega 3, the dose of omega-3 fatty acids will be determined by baseline weight (\<40 kg-450 mg/day, 40-60 kg-900 mg/day, >60 kg-1300 mg/day), daily doses of Ursodeoxycholic acid (UCD)( Ursofalk) in a dose of 20 mg/Kg/day in two divided doses depending on their body weight for 12 weeks and a 12-week exercise program for 30-45 min/day for 3 days/week. in the first two weeks and for 60 min/day for 4-5 days/week in the following weeks. In Arm(2), Patients will receive lifestyle modification according to NASPGHAN Clinical Guidelines for the treatment of NAFLD in Children. Patients will follow healthy and well-balanced diet. Patient caloric intake will be calculated according to the Recommended Daily Allowance (RDA) for age ) with avoidance of sugar-sweetened beverages, moderate- to high-intensity exercise daily will be encouraged, and screen time will be limited to less than 2 hours. The group of patients on chemothrapy will all receive arm(1) intervention without randomization,so as not to deprive them from the hypothecal benefit of the intervention.
LIVERFASt evaluation and imaging will be repeated by the end of the 12 week intervention period as follow up
Screening for NAFLD is appropriate because it can be detected before the onset of irreversible, end-stage liver disease. Identification of children with NAFLD is important because effective treatment is available. Although more challenging to implement than prescribing a medication, lifestyle intervention can be effective at reversing NAFLD and even NASH, particularly if initiated early in the course of disease, before advanced fibrosis has developed.
Although liver biopsy is the current standard to provide critical diagnostic and staging information, including the presence of NASH, and to eliminate alternative and/or concurrent diagnoses. Liver biopsy has inherent limitations for staging NAFLD because of the non uniformity of disease throughout the liver in reference to the small sample of liver obtained Other noninvasive methods used as screening tests for NAFLD include measurement of liver stiffness through transient elastography, which is an accurate and reproducible methodology to identify pediatric subjects without fibrosis or significant fibrosis, or with advanced fibrosis.
LIVERFASt (LF)is a panel of three non-invasive patented artificial intelligence neural networks algorithms estimating liver fibrosis (LF-Fib), inflammatory activity (LF-Act) and steatosis (LF-Ste) intended for the evaluation of NAFLD risk patients. It combines age, gender and BMI with ten serum biomarkers easy to determine in routine biochemistry in fasting patients that are independently correlated with the severity of each histological feature of nonalcoholic fatty liver disease (NAFLD).
This study evaluates the use of the LIVERFASt biomarkers as well as ultrasound (US) for early detection and staging of NAFLD, and the impact of a designed non-invasive therapeutic intervention in the form of Omega-3, Ursodeoxycholic acid and lifestyle modification, in 2 groups of children compared with a control group of healthy children age and gender matched.
6,578 studies on the registry are indexed under Obesity; 1,718 are open to participants now.
This study's planned enrollment of 200 is above the median of 77 across 5,084 interventional studies indexed under Obesity.
Browse Obesity studies →Ain Shams University is the lead sponsor of 1,932 studies on the registry; 433 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Children aged between 5-18 years, including:
Exclusion Criteria:
Patients will follow Mediterranean Diet (MD) for 12 weeks, this diet is characterized by a high intake of vegetables, fruit, whole cereals, legumes, nuts, and fish and a low intake of red meat and homemade desserts. The main added fat is extra virgin olive oil, with 35-40% kcal from fat (\<10% from saturated fat), 40-44% kcal from carbohydrate, and 20% kcal from protein. Patient caloric intake will be calculated according to the Recommended Daily Allowance (RDA) for age. Supplementation of omega 3, the dose of omega-3 fatty acids will be determined by baseline weight (\<40 kg-450 mg/day, 40-60 kg-900 mg/day, \>60 kg-1300 mg/day). Patients will also receive daily doses of Ursodeoxycholic acid (UCD) Ursofalk) in a dose of 20 mg/Kg/day in two divided doses depending on their body weight for 12 weeks. Patients will participate in a 12-week exercise program for 30-45 min/day for 3 days/week in the first 2 weeks and for 60 min/day for 4-5 days/week thereafter.
Drug: Ursodeoxycholic Acid 250 Mg Oral Capsule · Dietary Supplement: Omega -3 fatty acids · Behavioral: Physical exercise · Behavioral: Mediterrenean diet
Patients will receive lifestyle modification according to NASPGHAN Clinical Guidelines for the treatment of NAFLD in Children. Patients will follow healthy and well-balanced diet. Patient caloric intake will be calculated according to the Recommended Daily Allowance (RDA) for age with avoidance of sugar-sweetened beverages, moderate- to high-intensity exercise daily will be encouraged, and screen time will be limited to less than 2 hours.
Behavioral: Diet according to NASPGHAN guidelines
Daily doses of Ursodeoxycholic acid (UCD) Ursofalk) in a dose of 20 mg/Kg/day in two divided doses depending on their body weight for 12 weeks will be assigned to arm(1)
Supplementation of omega 3, the dose of omega-3 fatty acids will be determined by baseline weight (\<40 kg-450 mg/day, 40-60 kg-900 mg/day, \>60 kg-1300 mg/day) will be assigned to children in arm (1). Side effect such as gastrointestinal upset and allergy will be monitored, compliance will be monitored by weekly phone call
Patients assigned to arm (1) will participate in a 12-week exercise program for 30-45 min/day for 3 days/week. in the first two weeks and for 60 min/day for 4-5 days/week in the following weeks
Patients in arm (1) will follow Mediterranean Diet (MD) for 12 weeks, this diet is characterized by a high intake of vegetables, fruit, whole cereals, legumes, nuts, and fish and a low intake of red meat and homemade desserts. The main added fat is extra virgin olive oil, with 35-40% kcal from fat (\<10% from saturated fat), 40-44% kcal from carbohydrate, and 20% kcal from protein.( Plaz et al., 2019) Patient caloric intake will be calculated according to the Recommended Daily Allowance (RDA) for age. Compliance to the MD will be assessed in all patients using the KIDMED index at 4 ,8 and 12 weeks.Those who prove to be non-compliant will be excluded from the study.
Patients in arm (2) will receive lifestyle modification according to NASPGHAN Clinical Guidelines for the treatment of NAFLD in Children. Patients will follow healthy and well-balanced diet. Patient caloric intake will be calculated according to the Recommended Daily Allowance (RDA) for age, with avoidance of sugar-sweetened beverages, moderate- to high-intensity exercise daily will be encouraged, and screen time will be limited to less than 2 hours.
Study of the prevalence of liver steatosis, steatohepatitis and fibrosis among the study population by using LIVERFASt.
Study of the prevalence of liver steatosis, steatohepatitis and fibrosis among the study population by using LIVERFASt.
Time frame: 2 years
To compare the prevalence of NAFLD as estimated by LIVERFASt ,in two paediatric populations: who use chemotherapy for hematologic malignancies, and other who are at high risk of NAFLD(obese and overweighted)with apparently healthy controls matched for ge
To compare the prevalence of NAFLD as estimated by LIVERFASt ,in two paediatric populations: who use chemotherapy for hematologic malignancies, and other who are at high risk of NAFLD(obese and overweighted)with apparently healthy controls matched for gender and age.
Time frame: 2 years
To estimate the efficacy and safety of therapeutic interventions in the form of Omega-3 supplements, Ursodeoxycolic acid and life style changes by assessment of the side effects, and their efficacy on liver fibrosis, steatosis and steatohepatitis.
To estimate the efficacy and safety of therapeutic interventions in the form of Omega-3 supplements, Ursodeoxycolic acid and life style changes by assessment of the side effects, and their efficacy on liver fibrosis, steatosis and steatohepatitis.
Time frame: 2 years
Plan to share: Undecided — For the sake of patients' confidentiality and dignity
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for May 2025, 18 months after the start.
Of 112 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 81. This study's planned 18 months is below that.
Counting every sponsor, half of 127 studies reached it within 39 months; a quarter within 18 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ursodeoxycholic Acid · Omega-3 fatty acid